May 10, 2007 |
ELITE PHARMACEUTICALS TO PRESENT AT RODMAN & RENSHAW 4th ANNUAL GLOBAL HEALTHCARE CONFERENCE |
Northvale, New Jersey, Thursday, May 10, 2007: Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (AMEX: ELI), will be presenting at the Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo, Monaco on Monday, May 14th at 8:40 AM CEST. Bernard Berk, Chairman and Chief Executive Officer, will be providing an update on the Company’s developments and business strategy.
For those unable to attend the conference, a webcast of the presentation will broadcast “live,” and may be accessed by visiting Elite Pharmaceutical’s website, www.elitepharma.com. The presentation will also be available on the Company’s website for 90 days after the conference.
About Elite Pharmaceuticals Elite Pharmaceuticals is a specialty pharmaceutical company principally engaged in the development and manufacturing of oral controlled-release products. The Company's strategy includes developing generic versions of controlled release drug products with high barriers to entry and assisting partner companies in the life cycle management of products to improve off-patent drug products. Elite's technology is applicable to develop delayed, sustained or targeted release capsules or tablets. Elite has one product, a once-daily antihistamine, which is currently being sold commercially and a pipeline of eight drug products under development in the therapeutic areas that include pain management, allergy, cardiovascular disease and infection. Elite’s lead pipeline products are once-daily oxycodone to provide improved delivery of the drug for the patient and an abuse-resistant oxycodone formulated to discourage the illegal diversion and abuse of this drug. The addressable market for Elite's current pipeline of products exceeds $6 billion. Elite also has a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
FOR FURTHER INFORMATION, CONTACT: For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations Phone: 518-398-6222 Email: Dianne@elitepharma.com Website: www.elitepharma.com
This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of the Company, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. The Company undertakes no obligation to update any forward-looking statements. |
|